Jeffrey V. Poulton sold $1.7M of ALNY
EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC.. 3,821 shares at an average of $452.05, traded Oct 2, 2025, filed Oct 3, 2025.
Score components
- +22RoleCFO
- +25Trade size$1.7M at market
- 0Share of holdings soldSold 6.6% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000117, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | AGrant or award Common Stock | +3,108 | $0.00 | $0 | 53,229 | Oct 3, 2025 |
| Oct 1, 2025 | AGrant or award Common Stock | +4,644 | $0.00 | $0 | 57,873 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -150 | $446.53 | $67k | 57,723 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -73 | $447.92 | $33k | 57,650 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -234 | $448.77 | $105k | 57,416 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -324 | $449.79 | $146k | 57,092 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -704 | $450.81 | $317k | 56,388 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -432 | $451.86 | $195k | 55,956 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -869 | $452.69 | $393k | 55,087 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -428 | $453.77 | $194k | 54,659 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -317 | $454.84 | $144k | 54,342 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -95 | $455.82 | $43k | 54,247 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -191 | $457.43 | $87k | 54,056 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -4 | $457.64 | $1,831 | 54,052 | Oct 3, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $5.5M 12,128 shares | -36% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $12M 25,650 shares | -32% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $2.7M 5,959 shares | -23% | |
| 55Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 2,441 shares | -9% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $635k 1,405 shares | -5% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $4.0M 8,924 shares | -12% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8.4M 18,000 shares | -96% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $5.1M 11,250 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.